MAP2K7 and non-small cell lung carcinoma: Preclinical and clinical data from case reports suggest that the targeted therapy approach using the triple EGFR/BRAF/MEK pathway co-inhibition may be effective and well tolerated in patients with EGFR-mutant NSCLC and BRAF activation as an ARM to EGFR TKIs [25,26,27,29,30,42].